In Vivo |
Hydrangenol (5, 10, 20, 或 40 mg/kg; 口服; 每日给药,共 7 周) 减轻 uvb 照射 HR-1 无毛小鼠的皱纹形成、背厚、脱水和胶原蛋白降解[1]。 Animal Model: UVB-irradiated HR-1 hairless mice[1] Dosage: 5, 10, 20, or 40 mg/kg Administration: Oral gavage; daily for 7 weeks Result: Increased the expression of involucrin, filaggrin, and aquaporin-3 (AQP3) as well as hyaluronic acid (HA) production via hyaluronidase (HYAL)-1/-2 downregulation. Increased the expression of Pro-COL1A1. Decreased the expression matrix metalloproteinase (MMP)-1/-3, cyclooxygenase-2 (COX-2), and interleukin-6 (IL-6). Attenuated the phosphorylation of mitogen-activated protein kinases (MAPKs) including ERK and p38, activator protein 1 (AP-1) subunit, and signal transduction and activation of transcription 1 (STAT1). Upregulated the expression of nuclear factor-E2-related factor 2 (Nrf2), heme oxygenase-1 (HO-1), NAD(P)H quinone dehydrogenase 1 (NQO-1), glutamate cysteine ligase modifier subunit (GCLM), and glutamate cysteine ligase catalysis subunit (GCLC).
|